StockData
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) stock

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$5.50−0.38 (-6.46%)

Close on Nov 17, 2026Market cap $447.10MP/E –Yield –

Phathom Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Phathom Pharmaceuticals's price to sales ratio was 2.1× on Nov 11, 2026, against 7.5× a year earlier. Over the last 3 years it ranged from 1.9× to 266.7×, with a median of 7.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.1×−5.9
2025Dec 31, 20258.0×−13.1
2024Dec 31, 202421.1×–

More Phathom Pharmaceuticals figures

See a number that looks wrong?